Related Experiment Video
Updated: Jun 26, 2025
In vitro Cell Migration and Invasion Assays
Published on: June 1, 2014
In Vitro and In Vivo Studies of Melanoma Cell Migration by Antagonistic Mimetics of Adhesion Molecule L1CAM
Stefano Vito Boccadamo Pompili1,2, Sophia Fanzini2, Melitta Schachner3
1Department of Physiology and Pharmacology "V. Erspamer", Sapienza University, 00185 Rome, Italy.
Abstract:
Melanoma, the deadliest type of skin cancer, has a high propensity to metastasize to other organs, including the brain, lymph nodes, lungs, and bones. While progress has been made in managing melanoma with targeted and immune therapies, many patients do not benefit from these current treatment modalities. Tumor cell migration is the initial step for invasion and metastasis. A better understanding of the molecular mechanisms underlying metastasis is crucial for developing therapeutic strategies for metastatic diseases, including melanoma. The cell adhesion molecule L1CAM (CD171, in short L1) is upregulated in many human cancers, enhancing tumor cell migration. Earlier studies showed that the small-molecule antagonistic mimetics of L1 suppress glioblastoma cell migration in vitro. This study aims to evaluate if L1 mimetic antagonists can inhibit melanoma cell migration in vitro and in vivo. We showed that two antagonistic mimetics of L1, anagrelide and 2-hydroxy-5-fluoropyrimidine (2H5F), reduced melanoma cell migration in vitro. In in vivo allograft studies, only 2H5F-treated female mice showed a decrease in tumor volume.
Insights
Two L1 mimetics, anagrelide and 2-hydroxy-5-fluoropyrimidine (2H5F), reduced melanoma cell migration. Only 2H5F decreased tumor volume in vivo, suggesting potential for treating metastatic melanoma.
Area of Science:
- Oncology
- Cancer Biology
- Molecular Medicine
Background:
- Melanoma metastasis is a significant challenge, with many patients unresponsive to current therapies.
- Tumor cell migration is a critical early step in the invasion and metastasis of melanoma.
- The cell adhesion molecule L1CAM (L1) is implicated in cancer cell migration and metastasis.
Purpose of the Study:
- To investigate the efficacy of L1 mimetic antagonists in inhibiting melanoma cell migration.
- To evaluate the in vitro and in vivo effects of L1 antagonists on melanoma progression.
Main Methods:
- In vitro assessment of melanoma cell migration using anagrelide and 2-hydroxy-5-fluoropyrimidine (2H5F).
- In vivo evaluation of tumor volume reduction in a mouse allograft model following treatment with L1 mimetic antagonists.
Main Results:
- Both anagrelide and 2H5F demonstrated a reduction in melanoma cell migration in vitro.
- Treatment with 2H5F resulted in a significant decrease in tumor volume in female mice in vivo.
- Anagrelide did not show a significant effect on tumor volume in the in vivo model.
Conclusions:
- L1 mimetic antagonists show promise in inhibiting melanoma cell migration.
- 2-hydroxy-5-fluoropyrimidine (2H5F) exhibits therapeutic potential for reducing melanoma tumor growth in vivo.
- Targeting L1CAM may offer a novel strategy for managing metastatic melanoma.
Related Concept Videos
01:31Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
01:35Cancer Cell Migration through Invadopodia